AzTrials
AzTrials

Acute Lymphoblastic LeukemiaEwall Obs 2022NCT07684131

EWALL-PH OBSERVARTORY 2022

An observational study of Acute Lymphoblastic Leukemia, run by Versailles Hospital at 23 sites in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

An observatory for patients aged 18 years and over with Philadelphia chromosome positive (Ph+ or BCR::ABL1) acute lymphoblastic leukemia (ALL) and treated with the combination of BCR::ABL1 inhibitors and chemotherapy and/or corticosteroids and/or a monoclonal antibody. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Acute Lymphoblastic Leukemia
How many people
100 participants
Where
23 sitesFrance
Study dates
15 Jan 2024to 31 Dec 2027
How long will I take part?
5 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Acute Lmphoblastic Leukaemia with Philadelphia chromosome or BCR::ABL1 positive

Who may be able to join

  • Male or female patients ≥ 18 years
  • Philadelphia chromosome or BCR::ABL1 positive acute lymphoblastic leukaemia
  • Treatment with the combination of BCR::ABL1 inhibitors and chemotherapy and/or corticotherapy and/or a monoclonal antibody

Who cannot join

  • Patients deceded and having previously refused data collection
  • Not included in a prospective clinical trial

Trial locations and contacts

23 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Sandrine Roux contact

+33139239777

sroux@ght78sud.fr

23 sites in 1 country

France23 sites, 23 recruiting

  • Groupe hospitalier sud

    Amiens

    amandine charbonnie, md

    Not yet recruiting

  • CHU Angers

    Angers

    aline schmidt, md

    Not yet recruiting

  • CH de la cote basque

    Bayonne

    claudie capdupuy, MD

    Not yet recruiting

  • CHU Bordeaux

    Bordeaux

    Thibaut Leguay, MD

    Recruiting

  • Hopital Militaire Percy

    Clamart

    jean valère Malfuson, MD

    Not yet recruiting

  • CHU clermont ferrand

    Clermont-Ferrand

    victoria cacheux, MD

    Recruiting

  • Centre Hospitalier sud francilien

    Corbeil-Essonnes

    Stephanie Haiat, MD

    Recruiting

  • CHU de grenoble

    Grenoble

    martin carre, md

    Not yet recruiting

  • CHU Sud Réunion

    La Réunion

    quentin cabrera, md

    Not yet recruiting

  • CH Versailles

    Le Chesnay

    Philippe Rousselot, MD

    Recruiting

  • CH Le Mans

    Le Mans

    nathalie denizon, MD

    Recruiting

  • Chu de Lille

    Lille

    valérie Coiteux, md

    Not yet recruiting

  • Hopital de la conception

    Marseille

    julien colle, md

    Not yet recruiting

  • Institut Paoli Calmettes

    Marseille

    Aude Charbonnier, MD

    Not yet recruiting

  • CHRU de Nancy

    Nancy

    gabrielle roth guepin, md

    Not yet recruiting

  • Centre Antoine Lacassagne

    Nice, 06189

    Lauris Gastaud

    Not yet recruiting

  • Hopital Cochin

    Paris

    lise willems, md

    Not yet recruiting

  • Hopital necker

    Paris

    felipe suarez, MD

    Recruiting

  • Hopital St Louis

    Paris

    emmaunel Raffoux, md

    Recruiting

  • CH de Lyon

    Pierre-Bénite

    marie balsat, MD

    Not yet recruiting

  • CH St Etienne

    Saint-Etienne

    Emmanuelle Tavernier, md

    Not yet recruiting

  • ICANS

    Strasbourg

    karin bilger, MD

    Not yet recruiting

  • Hopital de Purpan

    Toulouse

    Francoise huguet, MD

    Not yet recruiting

Other trials in France

About this study

Official title: AN OBSERVATORY FOR PATIENTS AGED 18 YEARS AND OVER WITH PHILADELPHIA CHROMOSOME POSITIVE (PH+ OR BCR::ABL1+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) AND TREATED WITH THE COMBINATION OF BCR::ABL1 INHIBITORS AND CHEMOTHERAPY AND/OR CORTICOSTEROIDS AND/OR A MONOCLONAL ANTIBODY.

An observatory for patients aged 18 years and over with Philadelphia chromosome positive (Ph+ or BCR::ABL1) acute lymphoblastic leukemia (ALL) and treated with the combination of BCR::ABL1 inhibitors and chemotherapy and/or corticosteroids and/or a monoclonal antibody.

Medical subject headings
Precursor Cell Lymphoblastic Leukemia-Lymphoma

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Overall survival by 12 months

    Measured: 12 months

Secondary outcomes (10)

  1. overal survival by 36 months

    Measured: 36 months

  2. proportion of complete remission

    Measured: 36 months

  3. the molecular response defined by BCR//ABL1/ABL1 ratio in bone marrow and/or peripheral blood

    Measured: 36 months

  4. the molecular response defined by IGTR quantification proportion in bone marrow and/or peripheral blood

    Measured: 36 months

  5. Event free survival

    Measured: 36 months

  6. Relapse free survival

    Measured: 36 months

  7. the incidence ofBCR..ABL1 TK mutations

    Measured: 36 months

  8. treatment tolerance

    Measured: 36 months

  9. Death during induction

    Measured: 2 months

  10. Death in complete remission

    Measured: 36 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Jul 2026
  2. Study start15 Jan 2024
  3. Primary completion15 Jun 2027 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
100 participants (estimated)
Target duration
5 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT07684131
Sponsor's protocol ID
P22/10_EwallObs 2022
Acronym
Ewall Obs 2022
Status last verified
Apr 2026
First submitted
4 Apr 2026
Last updated
6 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Acute Lymphoblastic Leukemia, run by Versailles Hospital at 23 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 6 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 23 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Sandrine Roux (+33139239777, sroux@ght78sud.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Overall survival by 12 months (time frame: 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07684131.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jul 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in